Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Steris's Enterprise Value is R$110,108 Mil.
Steris's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was R$5,971 Mil. Therefore, Steris's EV-to-EBIT ratio for today is 18.44.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Steris's Enterprise Value is R$110,108 Mil.
Steris's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was R$8,596 Mil. Therefore, Steris's EV-to-EBITDA ratio for today is 12.81.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Steris's Enterprise Value is R$110,108 Mil.
Steris's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was R$32,016 Mil. Therefore, Steris's EV-to-Revenue ratio for today is 3.44.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Steris's Enterprise Value is R$110,108 Mil.
Steris's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was R$5,260 Mil. Therefore, Steris's EV-to-FCF ratio for today is 20.93.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Steris's current Enterprise Value is R$110,108 Mil.
Steris's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$5,971 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Steris's current Enterprise Value is R$110,108 Mil.
Steris's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$8,596 Mil.
Steris's current Enterprise Value is R$110,108 Mil.
Steris's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$32,016 Mil.
Steris's current Enterprise Value is R$110,108 Mil.
Steris's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$7,254 Mil.
Steris's current Enterprise Value is R$110,108 Mil.
Steris's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$5,260 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steris Enterprise Value Related Terms
Steris Enterprise Value Historical Data
* Premium members only.
The historical data trend for Steris's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:S1TE34 vs ZBH, GEHC, DXCM: Enterprise Value Comparison
For the Medical Devices subindustry, Steris's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Steris's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Steris's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of R$110,108 Mil mean?
Steris (BSP:S1TE34) has a Enterprise Value of R$110,108 Mil as of Aug. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Steris and its competitors.
Is Steris' Enterprise Value too high?
Steris' current Enterprise Value is R$110,108 Mil. Overall, Steris has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Steris' Enterprise Value compare to ZBH and GEHC?
Steris' Enterprise Value of R$110,108 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Steris and its competitors. Steris's current Enterprise Value is R$110,108 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Steris (BSP:S1TE34) has a current Enterprise Value of R$110,108 Mil. The stock's GF Value™ is R$60.72, compared to a current price of R$52.14 — trading 14.1% below its estimated fair value. The current Enterprise Value is R$110,108 Mil. Steris' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Steris (BSP:S1TE34), the current Enterprise Value is R$110,108 Mil as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (BSP:S1TE34) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of R$52.14 is trading 14.1% below its estimated GF Value™ of R$60.72.
Key valuation signals for BSP:S1TE34:
Enterprise Value: R$110,108 Mil
GF Value™: R$60.72 vs. price of R$52.14 (14.1% below fair value)
No single metric tells the full story. See the BSP:S1TE34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
23GF Score
Get the complete analysis for BSP:S1TE34
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:S1TE34 has been successfully added to your 
